bioMérieux S.A. (VIE:BIM)
Austria · Delayed Price · Currency is EUR | Market Cap | 8.29B -39.3% |
| Revenue (ttm) | 3.99B -3.2% |
| Net Income | 462.60M +22.4% |
| EPS | 3.90 +23.0% |
| Shares Out | n/a |
| PE Ratio | 17.91 |
| Forward PE | 15.58 |
| Dividend | 0.98 (1.36%) |
| Ex-Dividend Date | Jun 9, 2026 |
| Volume | n/a |
| Open | 72.00 |
| Previous Close | 71.85 |
| Day's Range | 72.00 - 72.70 |
| 52-Week Range | 66.25 - 117.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About bioMérieux
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of... [Read more]
Financial Performance
In 2025, bioMérieux's revenue was 4.07 billion, an increase of 2.26% compared to the previous year's 3.98 billion. Earnings were 397.50 million, a decrease of -8.03%.
Financial StatementsNews
bioMérieux Highlights Positive Impacts of Rapid, Accurate Diagnostics for Patients and Accepts Industry Awards at ADLM 2026
SALT LAKE CITY, Aug. 7, 2026 /PRNewswire/ -- bioMérieux, a world leader in the field of in vitro diagnostics, leveraged this year's 2026 Association for Diagnostics & Laboratory Medicine (ADLM) Annual...
bioMerieux price target lowered to EUR 75 from EUR 78 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on bioMerieux (BMXMF) to EUR 75 from EUR 78 and keeps a Hold rating on the shares.
bioMérieux Earnings Call Transcript: H1 2026
Q2 2026 delivered a strong rebound with 5% organic sales growth, offsetting a weak Q1 and supporting full-year guidance of 3%-5% sales growth and 0%-10% EBIT growth. Free cash flow surged 76% year-over-year, and the midterm outlook was revised to 3%-6% annual sales growth amid ongoing cost and market pressures.
bioMérieux Earnings release: H1 2026
bioMérieux released its H1 2026 earnings on July 28, 2026, summarizing the period's financial results.
bioMérieux Slides: H1 2026
bioMérieux has posted slides in relation to its H1 2026 quarterly earnings report, which was published on July 28, 2026.
bioMérieux Quarterly report: H1 2026
bioMérieux has published its H1 2026 quarterly earnings report on July 28, 2026.
bioMerieux downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley downgraded bioMerieux (BMXMF) to Underweight from Equal Weight with a price target of EUR 64, down from EUR 100. The firm sees a slowdown in respiratory volumes impacting…
bioMerieux price target lowered to EUR 78 from EUR 81 at Deutsche Bank
Deutsche Bank analyst Jan Koch lowered the firm’s price target on bioMerieux (BMXMF) to EUR 78 from EUR 81 and keeps a Hold rating on the shares. Published first on…
bioMerieux initiated with a Neutral at Piper Sandler
Piper Sandler initiated coverage of bioMerieux (BMXMF) with a Neutral rating and EUR 80 price target The firm launched coverage of the life science tools sector with a “feet in…
bioMerieux downgraded to Neutral from Buy at UBS
UBS downgraded bioMerieux (BMXMF) to Neutral from Buy with a price target of EUR 80, down from EUR 138. The company’s near-term visibility is less than previously assumed, the analyst…
bioMérieux Slides: FY 2026
bioMérieux has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 28, 2026.
bioMerieux price target lowered to EUR 71.60 from EUR 120.50 at JPMorgan
JPMorgan lowered the firm’s price target on bioMerieux (BMXMF) to EUR 71.60 from EUR 120.50 and keeps a Neutral rating on the shares.
bioMerieux downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Jan Koch downgraded bioMerieux (BMXMF) to Hold from Buy with a price target of EUR 81, down from EUR 120. The firm views the company’s profit warning…
bioMérieux Earnings Call Transcript: Q1 2026
Q1 2026 saw a 3.9% sales decline due to weak respiratory demand and geopolitical headwinds, but core reagent growth remained strong. Guidance for 2026 was revised down to 3%-5% sales growth and 0%-10% EBIT improvement, with cost controls and innovation initiatives ongoing.
bioMérieux Earnings release: Q1 2026
bioMérieux released its Q1 2026 earnings on April 23, 2026, summarizing the period's financial results.
bioMerieux price target lowered to EUR 100 from EUR 108 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on bioMerieux (BMXMF) to EUR 100 from EUR 108 and keeps an Equal Weight rating on the shares.
bioMérieux Earnings Call Transcript: H2 2025
Sales grew 6.2% organically to €4 billion in 2025, with EBIT up 16% and strong cash flow. 2026 guidance targets 5–7% sales growth and at least 10% EBIT growth, despite headwinds from China and currency. Price erosion remains limited and new launches are expected to drive future growth.
bioMérieux Earnings release: H2 2025
bioMérieux released its H2 2025 earnings on February 27, 2026, summarizing the period's financial results.
bioMérieux Slides: H2 2025
bioMérieux has posted slides in relation to its H2 2025 quarterly earnings report, which was published on February 27, 2026.
bioMérieux Annual report: H2 2025
bioMérieux has published its H2 2025 annual report on February 27, 2026.
bioMerieux price target lowered to EUR 100 from EUR 110 at Barclays
Barclays lowered the firm’s price target on bioMerieux (BMXMF) to EUR 100 from EUR 110 and keeps an Equal Weight rating on the shares.
bioMerieux price target lowered to EUR 109 from EUR 112 at Morgan Stanley
Morgan Stanley analyst Aisyah Noor lowered the firm’s price target on bioMerieux (BMXMF) to EUR 109 from EUR 112 and keeps an Equal Weight rating on the shares. Published first…
bioMerieux downgraded to Neutral from Outperform at BNP Paribas
BNP Paribas analyst Hugo Solvet downgraded bioMerieux (BMXMF) to Neutral from Outperform with a EUR 100 price target
bioMerieux price target lowered to EUR 112 from EUR 113 at Morgan Stanley
Morgan Stanley analyst Aisyah Noor lowered the firm’s price target on bioMerieux (BMXMF) to EUR 112 from EUR 113 and keeps an Equal Weight rating on the shares. Published first…
bioMerieux upgraded to Neutral from Underperform at BofA
BofA upgraded bioMerieux (BMXMF) to Neutral from Underperform with a price target of EUR 115, up from EUR 90. The firm thinks competitive headwinds are reflected in estimates, that internal…